Page last updated: 2024-12-06

cefonicid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Cefonicid is a broad-spectrum cephalosporin antibiotic that was synthesized in the 1970s. It is effective against a wide range of gram-positive and gram-negative bacteria, including Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus influenzae, and Escherichia coli. Cefonicid works by inhibiting the synthesis of bacterial cell walls, leading to cell lysis and death. It is typically administered intravenously or intramuscularly. Cefonicid is used to treat a variety of infections, including pneumonia, urinary tract infections, skin infections, and septicemia. It is also used as a prophylactic agent to prevent infections in patients undergoing surgery. Cefonicid is well-absorbed after intravenous or intramuscular administration and has a long half-life. It is primarily excreted in the urine. Cefonicid is generally well-tolerated, but it can cause adverse effects such as diarrhea, nausea, vomiting, and rash. In some cases, it can also cause more serious adverse effects, such as allergic reactions, seizures, and hepatotoxicity. Cefonicid is an important antibiotic, but its use has declined in recent years due to the emergence of antibiotic resistance. It is still used to treat certain infections, but it is not the first-line treatment for many infections. Cefonicid is studied to understand its mechanism of action, to identify new targets for antibiotic development, and to develop new strategies to overcome antibiotic resistance.'

Cefonicid: A second-generation cephalosporin administered intravenously or intramuscularly. Its bactericidal action results from inhibition of cell wall synthesis. It is used for urinary tract infections, lower respiratory tract infections, and soft tissue and bone infections. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

cefonicid : A cephalosporin bearing {[1-(sulfomethyl)-1H-tetrazol-5-yl]sulfanyl}methyl and (R)-2-hydroxy-2-phenylacetamido groups at positions 3 and 7, respectively, of the cephem skeleton. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID43594
CHEMBL ID1601
CHEBI ID3491
SCHEMBL ID60350
MeSH IDM0024188

Synonyms (44)

Synonym
BIDD:GT0667
(6r,7r)-7-{[(2r)-2-hydroxy-2-phenylacetyl]amino}-8-oxo-3-({[1-(sulfomethyl)-1h-tetrazol-5-yl]thio}methyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
cefonicid (inn)
D07644
monocef (tn)
cefonicid
C06882
61270-58-4
(6r,7r)-7-{[(2r)-2-hydroxy-2-phenylacetyl]amino}-8-oxo-3-({[1-(sulfomethyl)-1h-tetrazol-5-yl]sulfanyl}methyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DB01328
cefonicidum [inn-latin]
cefonicido [inn-spanish]
brn 1066181
5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((hydroxyphenylacetyl)amino)-8-oxo-3-(((1-sulfomethyl)-1h-tetrazol-5-yl)thio)methyl)-, (6r-(6-alpha,7-beta(r*)))-
cefonicid [inn:ban]
cefonicido
6beta-[(2r)-2-hydroxy-2-phenylacetamido]-3-({[1-(sulfomethyl)-1h-tetrazol-5-yl]sulfanyl}methyl)ceph-3-em-4-carboxylic acid
cefonicidum
CHEBI:3491 ,
(6r,7r)-7-[[(2r)-2-hydroxy-2-phenylacetyl]amino]-8-oxo-3-[[1-(sulfomethyl)tetrazol-5-yl]sulfanylmethyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
monocef
CHEMBL1601
(6r,7r)-8-oxidanylidene-7-[[(2r)-2-oxidanyl-2-phenyl-ethanoyl]amino]-3-[[1-(sulfomethyl)-1,2,3,4-tetrazol-5-yl]sulfanylmethyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
(6r,7r)-7-[[(2r)-2-hydroxy-1-oxo-2-phenylethyl]amino]-8-oxo-3-[[[1-(sulfomethyl)-5-tetrazolyl]thio]methyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
A833135
sk&f 75073
6532b86wfg ,
unii-6532b86wfg
SCHEMBL60350
cefonicid [who-dd]
(6r,7r)-7-(((2r)-2-hydroxy-2-phenylacetyl)amino)-8-oxo-3-(((1-(sulfomethyl)-1h-tetrazol-5-yl)thio)methyl)-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid
cefonicid [mi]
5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((2r)-2-hydroxy-2-phenylacetyl)amino)-8-oxo-3-(((1-(sulfomethyl)-1h-tetrazol-5-yl)thio)methyl)-, (6r,7r)-
cefonicid [inn]
cefonicid [vandf]
cefonicide
DYAIAHUQIPBDIP-AXAPSJFSSA-N
DTXSID7022758
(6r,7r)-7-[(2r)-2-hydroxy-2-phenylacetamido]-8-oxo-3-({[1-(sulfomethyl)-1h-1,2,3,4-tetrazol-5-yl]sulfanyl}methyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
(6r,7r)-7-((r)-2-hydroxy-2-phenylacetamido)-8-oxo-3-((1-(sulfomethyl)-1h-tetrazol-5-ylthio)methyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Q5057286
BRD-K34058848-304-03-1
EN300-92950
gtpl12217

Research Excerpts

Overview

Cefonicid is a new "second-generation" parenteral cephalosporin with an antibacterial spectrum similar to that of cefamandole. Cefoxitin (a cephamycin) and cep Halothin have uniquely different spectra of activity.

ExcerptReferenceRelevance
"Cefonicid is a new second-generation cephalosporin with a broad antimicrobial spectrum of activity and a prolonged serum elimination half-life. "( Cefonicid: a long-acting, second-generation cephalosporin. Antimicrobial activity, pharmacokinetics, clinical efficacy and adverse effects.
Kaye, D; Pontzer, RE,
)
3.02
"Cefonicid is an effective single-dose agent in uncomplicated lower urinary tract infection."( Single-dose regimen of cefonicid for the treatment of uncomplicated infections of the lower urinary tract.
Boscia, JA; Brannan, W; Cortez, LM; Guice, SL; Kaye, D; Krieger, RE; Levison, ME; McNamee, W; Morgan, SI; Pontzer, RE,
)
1.16
"Cefonicid is a new "second-generation" parenteral cephalosporin with an antibacterial spectrum similar to that of cefamandole. "( Comparison of cefonicid and cefamandole for the treatment of community-acquired infections of the lower respiratory tract.
Geckler, RW; Goodman, JS; McCormack, GD,
)
1.93
"Cefonicid is a new second-generation cephalosporin that has broad-spectrum antibacterial activity, achieves high peak serum concentrations, and has a long half-life. "( Treatment of bacterial osteomyelitis and Staphylococcus aureus endocarditis and single-dose therapy for uncomplicated Neisseria gonorrhoeae infections: an overview.
Mader, JT; Reinarz, JA,
)
1.57
"Cefonicid is a new cephalosporin with a spectrum of activity similar to that of cefamandole. "( Pharmacokinetic disposition of cefonicid in patients with renal failure and receiving hemodialysis.
Alexander, DP; Barriere, SL; Conte, JE; Gambertoglio, JG; Stagg, RJ,
)
1.86
"Cefonicid (SKF 75073) is a second-generation cephalosporin which has a spectrum of antimicrobial activity similar to that of cefamandole, but cefoxitin (a cephamycin) and cephalothin have uniquely different spectra of activity. "( Evaluation of the cefonicid disk test criteria, including disk quality control guidelines.
Barry, AL; Jones, RN; Thornsberry, C, 1983
)
2.04
"Cefonicid is a cephalosporin with a longer t1/2 than currently available cephalosporins. "( Cefonicid kinetics in subjects with normal and impaired renal function.
Blair, AD; Cutler, RE; Forland, SC; Jacob, L; Maxwell, BM, 1984
)
3.15
"Cefonicid is a new cephalosporin that, given in adequate concentrations is able to kill some pathogens such as Gram-positive cocci and many Enterobacteriaceae. "( Penetration of cefonicid into serum, salpinges, cervix and vaginal tissue.
Goisis, M; Grossi, F; Gusmitta, A; Soncini, R, 1991
)
2.08
"Cefonicid is a 'second generation' cephalosporin administered intravenously or intramuscularly. "( Cefonicid. A review of its antibacterial activity, pharmacological properties and therapeutic use.
Brogden, RN; Saltiel, E, 1986
)
3.16
"Cefonicid is a parenteral cephalosporin with a half-life of 4.5 hours, which permits once-daily dosing. "( Clinical efficacy of cefonicid in the treatment of staphylococcal infections.
Evrard, HM; Lentnek, AL; Phillips, SW; Sohn, CA; Wikler, MA, 1985
)
2.03

Effects

Cefonicid concentration has been determined microbiologically in cortical and medullary tissue in 30 patient undergoing surgery because of neoplastic disease. Cefazolin was given every eight hours.

ExcerptReferenceRelevance
"Cefonicid, which has an extended serum half-life, was administered once daily, while cefazolin was given every eight hours."( Antimicrobial prophylaxis for arthroplasty: a comparative study of cefonicid and cefazolin.
Davis, WA; Kane, JG, 1987
)
1.23
"Cefonicid has the advantage of once-daily dosing."( Comparison of cefonicid and cefazolin for treatment of soft-tissue infections.
Dall, L; Marzouk, J; Mills, J; Slutkin, G,
)
1.21
"Cefonicid concentration has been determined microbiologically in cortical and medullary tissue in 30 patient undergoing surgery because of neoplastic disease localized within the kidney. "( Cortical and medullary kidney tissue levels of cefonicid in human beings.
Comeri, G; Falchi, M; Ferrara, F; Fraschini, F; Maierna, G; Scaglione, F, 1989
)
1.98
"Cefonicid, which has an extended serum half-life, was administered once daily, while cefazolin was given every eight hours."( Antimicrobial prophylaxis for arthroplasty: a comparative study of cefonicid and cefazolin.
Davis, WA; Kane, JG, 1987
)
1.23

Toxicity

ExcerptReferenceRelevance
" Cefmetazole, at a dose of 1 g intramuscularly preoperatively, is a safe and effective agent for prophylaxis during hysterectomy."( Cefmetazole and cefonicid. Comparative efficacy and safety in preventing postoperative infections after vaginal and abdominal hysterectomy.
Azen, CG; Cendejas, KA; Essin, DJ; Galvan, NI; March, CM; Neal, J; Ressler, RL; Roy, S; Solera, NC; Wilkins, J, 1990
)
0.63
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32

Pharmacokinetics

The authors have explored the effects of cefonicid on the steady-state pharmacokinetics of a new sustained-release theophylline formulation in 12 adult patients suffering from chronic obstructive lung disease.

ExcerptReferenceRelevance
"The authors have explored the effects of cefonicid on the steady-state pharmacokinetics of a new sustained-release theophylline formulation in 12 adult patients suffering from chronic obstructive lung disease, by comparing the pharmacokinetic data obtained following four days of medication with theophylline alone with those found at the end of seven days of combined treatment with the same theophylline preparation plus cefonicid."( The effects of cefonicid on the pharmacokinetics of a once-a-day theophylline formulation.
Cazzola, M; D'Amato, G; Lobefalo, G; Lupis, F; Martucci, P; Vanacore, L, 1989
)
0.9
" Kinetic findings demonstrated a similar half-life for cefonicid in tissues and in serum."( Pharmacokinetics of cefonicid in serum and its penetration into lung tissue, bronchial mucosa and pleura.
Besa, G; Broccali, G; Furlan, G; Gusmitta, A, 1989
)
0.85
" Model-dependent and noncompartmental pharmacokinetic parameters were calculated and found to be congruous; noncompartmental data are reported."( Effect of age and renal function on cefonicid pharmacokinetics.
Ackerman, BH; Kearns, GL; Manning, JT; Monson, TP; Trang, JM; Underwood, FL, 1989
)
0.55
"kg-1 gave serum concentrations well within the therapeutic range for susceptible bacteria, and that its pharmacokinetic properties allow single daily doses to be used to treat infections in children."( Pharmacokinetics of cefonicid in children.
D'Elia, R; Furlanut, M; Pasinelli, F; Riva, E, 1989
)
0.6
" To determine the in vivo pharmacokinetic significance of these observations, the pharmacokinetics of both total and unbound (non-protein-bound) cefonicid was studied in six volunteers after a single intravenous dose of 30 mg/kg."( Effect of saturable serum protein binding on the pharmacokinetics of unbound cefonicid in humans.
Dudley, MN; Nightingale, CH; Quintiliani, R; Shyu, WC, 1986
)
0.7
" cefonicid dose produced high and prolonged plasma concentrations with a longer half-life than obtained with commonly used cephalosporins."( Cross-over study of the pharmacokinetics of cefonicid administered intravenously or intramuscularly to healthy adult humans.
Fillastre, JP; Fourtillan, JB; Humbert, G; Lefebvre, MA; Leroy, A; Ramis, N; Reumont, G,
)
1.3
"Knowledge of important pharmacokinetic parameters of a drug, such as its half-life in plasma and its distribution and body clearance, is helpful in understanding the time course of the plasma concentration of a drug as a function of dosage."( An overview of pharmacokinetics.
Cutler, RE,
)
0.13
" The pharmacokinetic disposition of the drug was examined in patients with various degrees of renal dysfunction and who were receiving hemodialysis."( Pharmacokinetic disposition of cefonicid in patients with renal failure and receiving hemodialysis.
Alexander, DP; Barriere, SL; Conte, JE; Gambertoglio, JG; Stagg, RJ,
)
0.42
"This study determined the pharmacokinetic disposition of cefonicid."( Pharmacokinetics of cefonicid, a new broad-spectrum cephalosporin.
Barriere, SL; Conte, JE; Gambertoglio, JG; Hatheway, GJ; Lin, ET, 1982
)
0.83

Bioavailability

ExcerptReferenceRelevance
"Three different intramuscular formulations of cefonicid (a new long acting cephalosporin) have been tested for bioavailability in 12 healthy volunteers, using a triple crossover design."( Bioavailability in human volunteers of three intramuscular formulations of cefonicid: a long-acting cephalosporin.
Brumfitt, W; Grady, D; Hamilton-Miller, JM; James, I; Price, C,
)
0.62

Dosage Studied

Cefonicid dosage can be reduced in proportion to decreases in creatinine clearance from normal levels. Because of high blood levels and long serum half-life, daily dosing is feasible. Dosage recommendations and clinical considerations for cefonicids use in continuous ambulatory peritoneal dialysis patients are discussed.

ExcerptRelevanceReference
" Dosage recommendations and clinical considerations for cefonicid use in continuous ambulatory peritoneal dialysis patients are discussed."( Peritoneal transport of cefonicid.
Curry, J; Deterding, J; Gal, P; Lane, T; Morse, GD; Nairn, DK, 1987
)
0.83
" Since cefonicid concentrations were within the therapeutic range for nearly all dosing intervals, we conclude that the guidelines used for dosage reduction and interval prolongation in this study result in therapeutically adequate concentrations in serum and, at the same time, result in no significant drug accumulation."( Multiple-dose pharmacokinetics of cefonicid in patients with impaired renal function.
Conte, JE; Phelps, RT, 1986
)
1.01
" Dosage of cefonicid should be adjusted according to the degree of renal impairment."( Pharmacokinetics of cefonicid in uraemic patients.
Fillastre, JP; Fourtillan, JB; Humbert, G; Lefevre, MA; Leroy, A; Ramis, N; Reumont, G, 1986
)
0.98
" This study may partially explain the poor results obtained with single daily dosing of cefonicid in endocarditis."( Effect of saturable serum protein binding on the pharmacokinetics of unbound cefonicid in humans.
Dudley, MN; Nightingale, CH; Quintiliani, R; Shyu, WC, 1986
)
0.72
" Smaller doses, longer dosing intervals and, potentially, a reduction in total drug cost may be the real advantage of these agents."( Review of the new second-generation cephalosporins: cefonicid, ceforanide, and cefuroxime.
Polk, RE; Tartaglione, TA, 1985
)
0.52
" Based on available data, single daily dosing of cefonicid in the therapy of Staph."( Review of cefonicid, a long-acting cephalosporin.
Dudley, MN; Nightingale, CH; Quintiliani, R,
)
0.79
" Because of high blood levels and long serum half-life, daily dosing with cefonicid is feasible."( Comparison of cefonicid and cefamandole for the treatment of community-acquired infections of the lower respiratory tract.
Geckler, RW; Goodman, JS; McCormack, GD,
)
0.72
", for all of the cephalosporins except cefoperazone and cefotaxime, modification of dosage is necessary when renal insufficiency is present."( An overview of pharmacokinetics.
Cutler, RE,
)
0.13
" Cefonicid dosage can be reduced in proportion to decreases in creatinine clearance from normal levels."( Pharmacokinetic disposition of cefonicid in patients with renal failure and receiving hemodialysis.
Alexander, DP; Barriere, SL; Conte, JE; Gambertoglio, JG; Stagg, RJ,
)
1.33
" These kinetic parameters were used to formulate dosage regimens for patients with renal impairment."( Cefonicid kinetics in subjects with normal and impaired renal function.
Blair, AD; Cutler, RE; Forland, SC; Jacob, L; Maxwell, BM, 1984
)
1.71
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
antibacterial drugA drug used to treat or prevent bacterial infections.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
cephalosporinA class of beta-lactam antibiotics differing from the penicillins in having a 6-membered, rather than a 5-membered, side ring. Although cephalosporins are among the most commonly used antibiotics in the treatment of routine infections, and their use is increasing over time, they can cause a range of hypersensitivity reactions, from mild, delayed-onset cutaneous reactions to life-threatening anaphylaxis in patients with immunoglobulin E (IgE)-mediated allergy.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (26)

Assay IDTitleYearJournalArticle
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID409958Inhibition of bovine brain MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (159)

TimeframeStudies, This Drug (%)All Drugs %
pre-199086 (54.09)18.7374
1990's62 (38.99)18.2507
2000's8 (5.03)29.6817
2010's1 (0.63)24.3611
2020's2 (1.26)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 38.55

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index38.55 (24.57)
Research Supply Index5.51 (2.92)
Research Growth Index4.26 (4.65)
Search Engine Demand Index56.64 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (38.55)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials49 (25.00%)5.53%
Reviews11 (5.61%)6.00%
Case Studies14 (7.14%)4.05%
Observational1 (0.51%)0.25%
Other121 (61.73%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Prospective Randomized Study to Compare Clinical Outcomes in Patients With Osteomyelitis Treated With Intravenous Antibiotics Versus Intravenous Antibiotics With an Early Switch to Oral Antibiotics [NCT02099240]Early Phase 111 participants (Actual)Interventional2014-03-06Terminated(stopped due to Not enough patient enrollment and lack of staffing)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]